collection
https://read.qxmd.com/read/25228002/dopaminergic-medication-does-not-improve-stepping-responses-following-backward-and-forward-balance-perturbations-in-patients-with-parkinson-s-disease
#1
JOURNAL ARTICLE
Digna de Kam, Jorik Nonnekes, Lars B Oude Nijhuis, Alexander C H Geurts, Bastiaan R Bloem, Vivian Weerdesteyn
In this study, we investigated the effect of dopaminergic medication on reactive stepping responses to forward and backward balance perturbations in patients with moderately severe Parkinson's disease (PD). Twelve PD patients, Hoehn and Yahr stage ranging from 2 to 3, and 15 healthy controls were exposed to multidirectional translational stance perturbations on a moveable platform. Perturbations were unpredictable in terms of amplitude, timing and direction. Patients were tested in the medication ON and OFF (at least 12 h of dopaminergic medication withdrawal) state on two separate days...
December 2014: Journal of Neurology
https://read.qxmd.com/read/25411441/csf-biomarkers-and-clinical-progression-of-parkinson-disease
#2
JOURNAL ARTICLE
Sara Hall, Yulia Surova, Annika Öhrfelt, Henrik Zetterberg, Daniel Lindqvist, Oskar Hansson
OBJECTIVE: To investigate whether certain CSF biomarkers at baseline can predict future progression of motor symptoms and cognitive decline in patients with Parkinson disease (PD). METHODS: Patients and controls were recruited from hospitals in southern Sweden as part of the prospective and longitudinal Swedish BioFinder Study. In the present study, we included 42 patients with PD and 69 controls who had clinical assessment and lumbar puncture at baseline. Baseline CSF samples were analyzed for α-synuclein (αSyn), β-amyloid 1-42 (Aβ42), tau, phosphorylated tau, and neurofilament light...
January 6, 2015: Neurology
https://read.qxmd.com/read/25143234/a-review-of-the-clinical-evidence-for-complementary-and-alternative-therapies-in-parkinson-s-disease
#3
JOURNAL ARTICLE
Danny Bega, Paulina Gonzalez-Latapi, Cindy Zadikoff, Tanya Simuni
No conventional treatment has been convincingly demonstrated to slow or stop the progression of Parkinson's disease (PD). Dopaminergic therapy is the gold standard for managing the motor disability associated with PD, but it falls short of managing all of the aspects of the disease that contribute to quality of life. Perhaps for this reason, an increasing number of patients are searching for a more holistic approach to healthcare. This is not to say that they are abandoning the standard and effective symptomatic therapies for PD, but rather are complementing them with healthy living, mind-body practices, and natural products that empower patients to be active participants in their healthcare and widen the net under which disease modification might one day be achieved...
October 2014: Current Treatment Options in Neurology
https://read.qxmd.com/read/25401511/clinical-correlations-with-lewy-body-pathology-in-lrrk2-related-parkinson-disease
#4
JOURNAL ARTICLE
Lorraine V Kalia, Anthony E Lang, Lili-Naz Hazrati, Shinsuke Fujioka, Zbigniew K Wszolek, Dennis W Dickson, Owen A Ross, Vivianna M Van Deerlin, John Q Trojanowski, Howard I Hurtig, Roy N Alcalay, Karen S Marder, Lorraine N Clark, Carles Gaig, Eduardo Tolosa, Javier Ruiz-Martínez, Jose F Marti-Masso, Isidre Ferrer, Adolfo López de Munain, Samuel M Goldman, Birgitt Schüle, J William Langston, Jan O Aasly, Maria T Giordana, Vincenzo Bonifati, Andreas Puschmann, Margherita Canesi, Gianni Pezzoli, Andre Maues De Paula, Kazuko Hasegawa, Charles Duyckaerts, Alexis Brice, A Jon Stoessl, Connie Marras
IMPORTANCE: Mutations in leucine-rich repeat kinase 2 (LRRK2) are the most common cause of genetic Parkinson disease (PD) known to date. The clinical features of manifesting LRRK2 mutation carriers are generally indistinguishable from those of patients with sporadic PD. However, some PD cases associated with LRRK2 mutations lack Lewy bodies (LBs), a neuropathological hallmark of PD. We investigated whether the presence or absence of LBs correlates with different clinical features in LRRK2-related PD...
January 2015: JAMA Neurology
https://read.qxmd.com/read/25385053/theta-burst-stimulation-over-the-supplementary-motor-area-in-parkinson-s-disease
#5
JOURNAL ARTICLE
Carsten Eggers, Miriam Günther, John Rothwell, Lars Timmermann, Diane Ruge
To investigate whether a period of continuous theta burst stimulation (cTBS) over the supplementary motor area (SMA) induces cortical plasticity and thus improves bradykinesia in Parkinson's disease (PD) in the medication ON and OFF state. In total, 26 patients with Parkinson's disease were tested with both real and sham stimulation. The group was divided into an OFF-medication (4 females, mean age 65 years, disease duration 6 years) and an ON-medication group (7 females, mean age 61 years, disease duration 7 years) with each containing 13 individuals...
February 2015: Journal of Neurology
https://read.qxmd.com/read/25381460/ancillary-investigations-to-diagnose-parkinsonism-a-prospective-clinical-study
#6
JOURNAL ARTICLE
M B Aerts, R A J Esselink, W F Abdo, F J A Meijer, G Drost, N Norgren, M J R Janssen, G F Borm, B R Bloem, M M Verbeek
Various ancillary investigations can assist clinicians in the differential diagnosis of patients with parkinsonism. It is unknown which test offers greatest diagnostic value in clinical practice. We included 156 consecutive patients with parkinsonism, but with an initially uncertain diagnosis. At baseline, all patients underwent extensive clinical testing and the following ancillary investigations: brain magnetic resonance imaging (MRI); (123)I-iodobenzamide single photon-emission computed tomography (IBZM-SPECT); analysis of cerebrospinal fluid (CSF); and anal sphincter electromyography (EMG)...
February 2015: Journal of Neurology
https://read.qxmd.com/read/24954673/imaging-insights-into-basal-ganglia-function-parkinson-s-disease-and-dystonia
#7
REVIEW
A Jon Stoessl, Stephane Lehericy, Antonio P Strafella
Recent advances in structural and functional imaging have greatly improved our ability to assess normal functions of the basal ganglia, diagnose parkinsonian syndromes, understand the pathophysiology of parkinsonism and other movement disorders, and detect and monitor disease progression. Radionuclide imaging is the best way to detect and monitor dopamine deficiency, and will probably continue to be the best biomarker for assessment of the effects of disease-modifying therapies. However, advances in magnetic resonance enable the separation of patients with Parkinson's disease from healthy controls, and show great promise for differentiation between Parkinson's disease and other akinetic-rigid syndromes...
August 9, 2014: Lancet
1
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.